Financings in Brief: SangStat
This article was originally published in The Gray Sheet
Executive Summary
SangStat: Adopts pre-emptive shareholder rights plan designed to protect stockholders from "partial tender offers, squeeze-outs, open market accumulations and other abusive tactics to gain control of the company without paying all stockholders a control premium," the firm announces Aug. 15. Under the plan, one preferred share purchase right will be issued Aug. 25 for each outstanding common stock share. The right enables shareholders "to buy one one-hundredth of a share of a new series of junior participating preferred stock at an exercise price of $45 upon certain events," the firm explains. The rights will be exercisable if a person or group acquires or makes a tender offer for 15% or more of the company's common stock...
You may also be interested in...
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.